Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Darell Bigner

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Living Beings

Chemicals & Drugs

Procedures

Anatomy

Concepts & Ideas

Tissue Distribution

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Sampson John H; Archer Gary E; Mitchell Duane A; Heimberger Amy B; Herndon James E; Lally-Goss Denise; McGehee-Norman Sharon; Paolino Alison; Reardon David A; Friedman Allan H; Friedman Henry S; Bigner Darell D
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Choi Bryan D; Archer Gary E; Mitchell Duane A; Heimberger Amy B; McLendon Roger E; Bigner Darell D; Sampson John H
EGFRvIII-targeted vaccination therapy of malignant glioma.
Graner Michael W; Raynes Deborah A; Bigner Darell D; Guerriero Vince
Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Darell Bigner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Sampson John H; Archer Gary E; Mitchell Duane A; Heimberger Amy B; Herndon James E; Lally-Goss Denise; McGehee-Norman Sharon; Paolino Alison; Reardon David A; Friedman Allan H; Friedman Henry S; Bigner Darell D
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Molecular cancer therapeutics 2009;8(10):2773-9.
2009: Choi Bryan D; Archer Gary E; Mitchell Duane A; Heimberger Amy B; McLendon Roger E; Bigner Darell D; Sampson John H
EGFRvIII-targeted vaccination therapy of malignant glioma.
Brain pathology (Zurich, Switzerland) 2009;19(4):713-23.
2009: Graner Michael W; Raynes Deborah A; Bigner Darell D; Guerriero Vince
Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces.
Cancer science 2009;100(10):1870-9.
2009: Bektas Meryem; Johnson Stewart P; Poe William E; Bigner Darell D; Friedman Henry S
A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
Cancer chemotherapy and pharmacology 2009;64(5):1053-8.
2009: Quinn Jennifer A; Jiang Sara Xiaoyin; Reardon David A; Desjardins Annick; Vredenburgh James J; Rich Jeremy N; Gururangan Sridharan; Friedman Allan H; Bigner Darell D; Sampson John H; McLendon Roger E; Herndon James E; Walker Amy; Friedman Henry S
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Neuro-oncology 2009;11(5):556-61.
2009: Boskovitz Abraham; McLendon Roger E; Okamura Tatsunori; Sampson John H; Bigner Darell D; Zalutsky Michael R
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
Nuclear medicine and biology 2009;36(6):659-69.
2009: Adamson Cory; Kanu Okezie O; Mehta Ankit I; Di Chunhui; Lin Ningjing; Mattox Austin K; Bigner Darell D
Glioblastoma multiforme: a review of where we have been and where we are going.
Expert opinion on investigational drugs 2009;18(8):1061-83.
2009: Affronti Mary Lou; Heery Christopher R; Herndon James E; Rich Jeremy N; Reardon David A; Desjardins Annick; Vredenburgh James J; Friedman Allan H; Bigner Darell D; Friedman Henry S
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Cancer 2009;115(15):3501-11.
2009: Kanu Okezie O; Mehta Ankit; Di Chunhui; Lin Ningjing; Bortoff Kathy; Bigner Darell D; Yan Hai; Adamson David Cory
Glioblastoma multiforme: a review of therapeutic targets.
Expert opinion on therapeutic targets 2009;13(6):701-18.
2009: Cui B; Johnson S P; Bullock N; Ali-Osman F; Bigner D D; Friedman H S
Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway.
Molecular pharmacology 2009;75(6):1356-63.
2009: Graner Michael W; Alzate Oscar; Dechkovskaia Angelika M; Keene Jack D; Sampson John H; Mitchell Duane A; Bigner Darell D
Proteomic and immunologic analyses of brain tumor exosomes.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2009;23(5):1541-57.
2009: Il'yasova Dora; McCarthy Bridget; Marcello Jennifer; Schildkraut Joellen M; Moorman Patricia G; Krishnamachari Bhuma; Ali-Osman Francis; Bigner Darell D; Davis Faith
Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(4):1232-8.
2009: Il'yasova Dora; McCarthy Bridget J; Erdal Serap; Shimek Joanna; Goldstein Jennifer; Doerge Daniel R; Myers Steven R; Vineis Paolo; Wishnok John S; Swenberg James A; Bigner Darell D; Davis Faith G
Human exposure to selected animal neurocarcinogens: a biomarker-based assessment and implications for brain tumor epidemiology.
Journal of toxicology and environmental health. Part B, Critical reviews 2009;12(3):175-87.
2009: Quinn Jennifer A; Jiang Sara Xiaoyin; Reardon David A; Desjardins Annick; Vredenburgh James J; Rich Jeremy N; Gururangan Sridharan; Friedman Allan H; Bigner Darell D; Sampson John H; McLendon Roger E; Herndon James E; Walker Amy; Friedman Henry S
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(8):1262-7.
2009: Bacolod Manny D; Fehdrau Randy; Johnson Stewart P; Bullock Nancy S; Bigner Darell D; Colvin Michael; Friedman Henry S
BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line.
Cancer chemotherapy and pharmacology 2009;63(4):753-8.
2009: Yan Hai; Parsons D Williams; Jin Genglin; McLendon Roger; Rasheed B Ahmed; Yuan Weishi; Kos Ivan; Batinic-Haberle Ines; Jones Siân; Riggins Gregory J; Friedman Henry; Friedman Allan; Reardon David; Herndon James; Kinzler Kenneth W; Velculescu Victor E; Vogelstein Bert; Bigner Darell D
IDH1 and IDH2 mutations in gliomas.
The New England journal of medicine 2009;360(8):765-73.
2009: Quinn Jennifer A; Jiang Sara Xiaoyin; Carter James; Reardon David A; Desjardins Annick; Vredenburgh James J; Rich Jeremy N; Gururangan Sridharan; Friedman Allan H; Bigner Darell D; Sampson John H; McLendon Roger E; Herndon James E; Threatt Stevie; Friedman Henry S
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(3):1064-8.
2009: Liu Yingmiao; Kuan Chien-Tsun; Mi Jing; Zhang Xiuwu; Clary Bryan M; Bigner Darell D; Sullenger Bruce A
Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.
Biological chemistry 2009;390(2):137-44.
2008: Desjardins Annick; Reardon David A; Herndon James E; Marcello Jennifer; Quinn Jennifer A; Rich Jeremy N; Sathornsumetee Sith; Gururangan Sridharan; Sampson John; Bailey Leighann; Bigner Darell D; Friedman Allan H; Friedman Henry S; Vredenburgh James J
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7068-73.
2008: Schmittling Robert J; Archer Gary E; Mitchell Duane A; Heimberger Amy; Pegram Charles; Herndon James E; Friedman Henry S; Bigner Darell D; Sampson John H
Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
Journal of immunological methods 2008;339(1):74-81.
2008: Sampson John H; Archer Gary E; Mitchell Duane A; Heimberger Amy B; Bigner Darell D
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Seminars in immunology 2008;20(5):267-75.
2008: Maxwell Jill A; Johnson Stewart P; McLendon Roger E; Lister David W; Horne Krystle S; Rasheed Ahmed; Quinn Jennifer A; Ali-Osman Francis; Friedman Allan H; Modrich Paul L; Bigner Darell D; Friedman Henry S
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(15):4859-68.
2008: Sampson John H; Akabani Gamal; Archer Gerald E; Berger Mitchel S; Coleman R Edward; Friedman Allan H; Friedman Henry S; Greer Kim; Herndon James E; Kunwar Sandeep; McLendon Roger E; Paolino Alison; Petry Neil A; Provenzale James M; Reardon David A; Wong Terence Z; Zalutsky Michael R; Pastan Ira; Bigner Darell D
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
Neuro-oncology 2008;10(3):320-9.
2008: Bacolod M D; Lin S M; Johnson S P; Bullock N S; Colvin M; Bigner D D; Friedman H S
The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.
Current cancer drug targets 2008;8(3):172-9.
2008: Everson Richard G; Graner Michael W; Gromeier Matthias; Vredenburgh James J; Desjardins Annick; Reardon David A; Friedman Henry S; Friedman Allan H; Bigner Darell D; Sampson John H
Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Expert review of anticancer therapy 2008;8(5):717-32.
2008: Reardon David A; Zalutsky Michael R; Akabani Gamal; Coleman R Edward; Friedman Allan H; Herndon James E; McLendon Roger E; Pegram Charles N; Quinn Jennifer A; Rich Jeremy N; Vredenburgh James J; Desjardins Annick; Guruangan Sridharan; Boulton Susan; Raynor Renee H; Dowell Jeanette M; Wong Terence Z; Zhao Xiao-Guang; Friedman Henry S; Bigner Darell D
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Neuro-oncology 2008;10(2):182-9.
2008: Mott Ryan T; Turner Kristi C; Bigner Darell D; McLendon Roger E
Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.
Journal of neurosurgery 2008;108(2):330-5.
2008: Heimberger Amy B; Sun Wei; Hussain S Farzana; Dey Mahua; Crutcher Lamonne; Aldape Ken; Gilbert Mark; Hassenbusch Samuel J; Sawaya Raymond; Schmittling Bob; Archer Gary E; Mitchell Duane A; Bigner Darell D; Sampson John H
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Neuro-oncology 2008;10(1):98-103.
2008: Yoshimoto Koji; Dang Julie; Zhu Shaojun; Nathanson David; Huang Tiffany; Dumont Rebecca; Seligson David B; Yong William H; Xiong Zhenggang; Rao Nagesh; Winther Henrik; Chakravarti Arnab; Bigner Darell D; Mellinghoff Ingo K; Horvath Steve; Cavenee Webster K; Cloughesy Timothy F; Mischel Paul S
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):488-93.
2008: Zalutsky Michael R; Reardon David A; Akabani Gamal; Coleman R Edward; Friedman Allan H; Friedman Henry S; McLendon Roger E; Wong Terence Z; Bigner Darell D
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(1):30-8.
2008: Ochiai Hidenobu; Archer Gary E; Herndon James E; Kuan Chien-Tsun; Mitchell Duane A; Bigner Darell D; Pastan Ira H; Sampson John H
EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.
Cancer immunology, immunotherapy : CII 2008;57(1):115-21.
2007: Johnson Stewart P; Kamen Barton A; Bigner Darell D; Friedman Henry S
O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines.
Cancer chemotherapy and pharmacology 2007;60(6):883-9.
2007: Vredenburgh James J; Desjardins Annick; Herndon James E; Marcello Jennifer; Reardon David A; Quinn Jennifer A; Rich Jeremy N; Sathornsumetee Sith; Gururangan Sridharan; Sampson John; Wagner Melissa; Bailey Leighann; Bigner Darell D; Friedman Allan H; Friedman Henry S
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4722-9.
2007: Graner Michael W; Cumming R Ian; Bigner Darell D
The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2007;27(42):11214-27.
2007: Zalutsky Michael R; Reardon David A; Pozzi Oscar R; Vaidyanathan Ganesan; Bigner Darell D
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
Nuclear medicine and biology 2007;34(7):779-85.
2007: Hjelmeland Anita B; Lattimore Kathryn P; Fee Brian E; Shi Qing; Wickman Sarah; Keir Stephen T; Hjelmeland Mark D; Batt David; Bigner Darell D; Friedman Henry S; Rich Jeremy N
The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.
Molecular cancer therapeutics 2007;6(9):2449-57.
2007: Badruddoja Michael A; Keir Stephen T; King Ivan; Zeidner Joseph; Vredenburgh James J; Muhlbaier Lawrence H; Bigner Darell D; Friedman Henry S
Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
Neuro-oncology 2007;9(3):240-4.
2007: Sampson John H; Raghavan Raghu; Brady Martin L; Provenzale James M; Herndon James E; Croteau David; Friedman Allan H; Reardon David A; Coleman R Edward; Wong Terence; Bigner Darell D; Pastan Ira; Rodríguez-Ponce María Inmaculada; Tanner Philipp; Puri Raj; Pedain Christoph
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.
Neuro-oncology 2007;9(3):343-53.
2007: Shi Qing; Hjelmeland Anita B; Keir Stephen T; Song Linhua; Wickman Sarah; Jackson Dowdy; Ohmori Osamu; Bigner Darell D; Friedman Henry S; Rich Jeremy N
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Molecular carcinogenesis 2007;46(6):488-96.
2007: Shi Q; Bao S; Song L; Wu Q; Bigner D D; Hjelmeland A B; Rich J N
Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.
Oncogene 2007;26(28):4084-94.
2007: McLendon Roger E; Akabani Gamal; Friedman Henry S; Reardon David A; Cleveland Linda; Cokgor Ilkcan; Herndon James E; Wikstrand Carol; Boulton Susan T; Friedman Allan H; Bigner Darell D; Zalutsky Michael R
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
Nuclear medicine and biology 2007;34(4):405-13.
2007: Reardon David A; Zalutsky Michael R; Bigner Darell D
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
Expert review of anticancer therapy 2007;7(5):675-87.
2007: Fecci Peter E; Ochiai Hidenobu; Mitchell Duane A; Grossi Peter M; Sweeney Alison E; Archer Gary E; Cummings Thomas; Allison James P; Bigner Darell D; Sampson John H
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2158-67.
2007: Jones Lee W; Guill Bebe; Keir Stephen T; Carter Karen; Friedman Henry S; Bigner Darell D; Reardon David A
Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer.
Psycho-oncology 2007;16(3):232-40.
2007: Vredenburgh James J; Desjardins Annick; Herndon James E; Dowell Jeannette M; Reardon David A; Quinn Jennifer A; Rich Jeremy N; Sathornsumetee Sith; Gururangan Sridharan; Wagner Melissa; Bigner Darell D; Friedman Allan H; Friedman Henry S
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1253-9.
2007: Yordanov Alexander T; Hens Marc; Pegram Charles; Bigner Darell D; Zalutsky Michael R
Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Nuclear medicine and biology 2007;34(2):173-83.
2007: Sampson John H; Brady Martin L; Petry Neil A; Croteau David; Friedman Allan H; Friedman Henry S; Wong Terence; Bigner Darell D; Pastan Ira; Puri Raj K; Pedain Christoph
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.
Neurosurgery 2007;60(2 Suppl 1):ONS89-98; discussion ONS98-9.
2007: Badruddoja Michael A; Penne Kara; Desjardins Annick; Reardon David A; Rich Jeremy N; Quinn Jennifer A; Sathornsumetee Sith; Friedman Allan H; Bigner Darell D; Herndon James E; Cahill Ann; Friedman Henry S; Vredenburgh James J
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
Neuro-oncology 2007;9(1):70-4.
2007: Jones Lee W; Guill Bebe; Keir Stephen T; Carter Karen; Friedman Henry S; Bigner Darell D; Reardon David A
Exercise interest and preferences among patients diagnosed with primary brain cancer.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007;15(1):47-55.
2006: Bao Shideng; Wu Qiulian; McLendon Roger E; Hao Yueling; Shi Qing; Hjelmeland Anita B; Dewhirst Mark W; Bigner Darell D; Rich Jeremy N
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
Nature 2006;444(7120):756-60.
2006: Maxwell Jill A; Johnson Stewart P; Quinn Jennifer A; McLendon Roger E; Ali-Osman Francis; Friedman Allan H; Herndon James E; Bierau Katja; Bigley Joseph; Bigner Darell D; Friedman Henry S
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.
Molecular cancer therapeutics 2006;5(10):2531-9.
2006: Sok John C; Coppelli Francesca M; Thomas Sufi M; Lango Miriam N; Xi Sichuan; Hunt Jennifer L; Freilino Maria L; Graner Michael W; Wikstrand Carol J; Bigner Darell D; Gooding William E; Furnari Frank B; Grandis Jennifer R
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5064-73.
2006: Sathornsumetee Sith; Hjelmeland Anita B; Keir Stephen T; McLendon Roger E; Batt David; Ramsey Timothy; Yusuff Naeem; Rasheed B K Ahmed; Kieran Mark W; Laforme Andrea; Bigner Darell D; Friedman Henry S; Rich Jeremy N
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
Cancer research 2006;66(17):8722-30.
2006: Bao Shideng; Wu Qiulian; Sathornsumetee Sith; Hao Yueling; Li Zhizhong; Hjelmeland Anita B; Shi Qing; McLendon Roger E; Bigner Darell D; Rich Jeremy N
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.
Cancer research 2006;66(16):7843-8.
2006: Fecci Peter E; Sweeney Alison E; Grossi Peter M; Nair Smita K; Learn Christopher A; Mitchell Duane A; Cui Xiuyu; Cummings Thomas J; Bigner Darell D; Gilboa Eli; Sampson John H
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4294-305.
2006: Vaidyanathan Ganesan; Alston Kevin L; Bigner Darrel D; Zalutsky Michael R
Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.
Bioconjugate chemistry 2006;17(4):1085-92.
2006: Reardon David A; Quinn Jennifer A; Akabani Gamal; Coleman R Edward; Friedman Allan H; Friedman Henry S; Herndon James E; McLendon Roger E; Pegram Charles N; Provenzale James M; Dowell Jeannette M; Rich Jeremy N; Vredenburgh James J; Desjardins Annick; Sampson John H; Gururangan Sridharan; Wong Terence Z; Badruddoja Michael A; Zhao Xiao-Guang; Bigner Darell D; Zalutsky Michael R
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(6):912-8.
2006: Graner Michael W; Bigner Darell D
Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.
Expert review of anticancer therapy 2006;6(5):679-95.
2006: Jones Lee W; Guill Bebe; Keir Stephen T; Carter B S Karen; Friedman Henry S; Bigner Darrell D; Reardon David A
Patterns of exercise across the cancer trajectory in brain tumor patients.
Cancer 2006;106(10):2224-32.
2006: Kuan Chien-Tsun; Wakiya Kenji; Dowell Jeannette M; Herndon James E; Reardon David A; Graner Michael W; Riggins Gregory J; Wikstrand Carol J; Bigner Darell D
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):1970-82.
2006: Fecci Peter E; Mitchell Duane A; Whitesides John F; Xie Weihua; Friedman Allan H; Archer Gary E; Herndon James E; Bigner Darell D; Dranoff Glenn; Sampson John H
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
Cancer research 2006;66(6):3294-302.
2006: Reardon David A; Rich Jeremy N; Friedman Henry S; Bigner Darell D
Recent advances in the treatment of malignant astrocytoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(8):1253-65.
2006: Reardon David A; Quinn Jennifer A; Vredenburgh James J; Gururangan Sridharan; Friedman Allan H; Desjardins Annick; Sathornsumetee Sith; Herndon James E; Dowell Jeannette M; McLendon Roger E; Provenzale James M; Sampson John H; Smith Robert P; Swaisland Alan J; Ochs Judith S; Lyons Peggy; Tourt-Uhlig Sandy; Bigner Darell D; Friedman Henry S; Rich Jeremy N
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):860-8.
2006: Davis Faith G; Erdal Serap; Williams Lori; Bigner Darell
Work exposures to animal neurocarcinogens.
International journal of occupational and environmental health 2006;12(1):16-23.
2006: Shankar Sriram; Vaidyanathan Ganesan; Kuan Chien-Tsun; Bigner Darell D; Zalutsky Michael R
Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Nuclear medicine and biology 2006;33(1):101-10.
2006: Reardon David A; Akabani Gamal; Coleman R Edward; Friedman Allan H; Friedman Henry S; Herndon James E; McLendon Roger E; Pegram Charles N; Provenzale James M; Quinn Jennifer A; Rich Jeremy N; Vredenburgh James J; Desjardins Annick; Gururangan Sridharan; Badruddoja Michael; Dowell Jeanette M; Wong Terence Z; Zhao Xiao-Guang; Zalutsky Michael R; Bigner Darell D
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):115-22.
2006: Sampson John H; Akabani Gamal; Friedman Allan H; Bigner Darell; Kunwar Sandeep; Berger Mitchel S; Bankiewicz Krystof S
Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.
Neurosurgical focus 2006;20(4):E14.
2005: Hjelmeland Anita B; Hjelmeland Mark D; Shi Qing; Hart Janet L; Bigner Darell D; Wang Xiao-Fan; Kontos Christopher D; Rich Jeremy N
Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity.
Cancer research 2005;65(24):11276-81.
2005: Yamaguchi Keisuke; Richardson Mark D; Bigner Darrell D; Kwatra Madan M
Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta.
Cancer chemotherapy and pharmacology 2005;56(6):585-93.
2005: Rich Jeremy N; Sathornsumetee Sith; Keir Stephen T; Kieran Mark W; Laforme Andrea; Kaipainen Arja; McLendon Roger E; Graner Michael W; Rasheed B K Ahmed; Wang Ling; Reardon David A; Ryan Anderson J; Wheeler Catherine; Dimery Isaiah; Bigner Darell D; Friedman Henry S
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(22):8145-57.
2005: Friedman Henry S; Bigner Darell D
Glioblastoma multiforme and the epidermal growth factor receptor.
The New England journal of medicine 2005;353(19):1997-9.
2005: Chang Susan M; Reynolds Sharon L; Butowski Nicholas; Lamborn Kathleen R; Buckner Jan C; Kaplan Richard S; Bigner Darell D
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.
Neuro-oncology 2005;7(4):425-34.
2005: Rizzieri David A; Wadleigh Martha; Wikstrand Carol J; Mann Karen P; Sen Filiz; Peterson Bercedis L; Niedzwiecki Donna; Proia Alan D; Bigner Darell D
Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity.
Leukemia & lymphoma 2005;46(10):1455-62.
2005: Quinn Jennifer A; Desjardins Annick; Weingart Jon; Brem Henry; Dolan M Eileen; Delaney Shannon M; Vredenburgh James; Rich Jeremy; Friedman Allan H; Reardon David A; Sampson John H; Pegg Anthony E; Moschel Robert C; Birch Robert; McLendon Roger E; Provenzale James M; Gururangan Sridharan; Dancey Janet E; Maxwell Jill; Tourt-Uhlig Sandra; Herndon James E; Bigner Darell D; Friedman Henry S
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7178-87.
2005: McLendon Roger E; Herndon James E; West Bryan; Reardon David; Wiltshire Rodney; Rasheed B K Ahmed; Quinn Jennifer; Friedman Henry S; Friedman Allan H; Bigner Darell D
Survival analysis of presumptive prognostic markers among oligodendrogliomas.
Cancer 2005;104(8):1693-9.
2005: Cheng C Lynn; Johnson Stewart P; Keir Stephen T; Quinn Jennifer A; Ali-Osman Francis; Szabo Csaba; Li Hongshan; Salzman Andrew L; Dolan M Eileen; Modrich Paul; Bigner Darell D; Friedman Henry S
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Molecular cancer therapeutics 2005;4(9):1364-8.
2005: Graner Michael W; Bigner Darell D
Chaperone proteins and brain tumors: potential targets and possible therapeutics.
Neuro-oncology 2005;7(3):260-78.
2005: Akabani Gamal; Reardon David A; Coleman R Edward; Wong Terence Z; Metzler Scott D; Bowsher James E; Barboriak Daniel P; Provenzale James M; Greer Kim L; DeLong David; Friedman Henry S; Friedman Allan H; Zhao Xiao-Guang; Pegram Charles N; McLendon Roger E; Bigner Darell D; Zalutsky Michael R
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(6):1042-51.
2005: Rich Jeremy N; Hans Christopher; Jones Beatrix; Iversen Edwin S; McLendon Roger E; Rasheed B K Ahmed; Dobra Adrian; Dressman Holly K; Bigner Darell D; Nevins Joseph R; West Mike
Gene expression profiling and genetic markers in glioblastoma survival.
Cancer research 2005;65(10):4051-8.
2005: Di Chunhui; Liao Shaoxi; Adamson David C; Parrett Timothy J; Broderick Daniel K; Shi Qun; Lengauer Christoph; Cummins Jordan M; Velculescu Victor E; Fults Daniel W; McLendon Roger E; Bigner Darell D; Yan Hai
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid.
Cancer research 2005;65(3):919-24.
2005: Sampson John H; Reardon David A; Friedman Allan H; Friedman Henry S; Coleman R Edward; McLendon Roger E; Pastan Ira; Bigner Darell D
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.
Neuro-oncology 2005;7(1):90-6.
2005: Goudar Ranjit K; Shi Qing; Hjelmeland Mark D; Keir Stephen T; McLendon Roger E; Wikstrand Carol J; Reese Elizabeth D; Conrad Charles A; Traxler Peter; Lane Heidi A; Reardon David A; Cavenee Webster K; Wang Xiao-Fan; Bigner Darell D; Friedman Henry S; Rich Jeremy N
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
Molecular cancer therapeutics 2005;4(1):101-12.
2005: Parekh Kalpaj; Ramachandran Sabarinathan; Cooper Joel; Bigner Darell; Patterson Alexander; Mohanakumar T
Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.
Lung cancer (Amsterdam, Netherlands) 2005;47(1):17-29.
2005: Desjardins Annick; Rich Jeremy N; Quinn Jennifer A; Vredenburgh James; Gururangan Sridharan; Sathornsumetee Sith; Reardon David A; Friedman Allan H; Bigner Darell D; Friedman Henry S
Chemotherapy and novel therapeutic approaches in malignant glioma.
Frontiers in bioscience : a journal and virtual library 2005;10():2645-68.
2004: Shi Qing; Bao Shideng; Maxwell Jill A; Reese Elizabeth D; Friedman Henry S; Bigner Darell D; Wang Xiao-Fan; Rich Jeremy N
Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation.
The Journal of biological chemistry 2004;279(50):52200-9.
2004: Purev Enkhtsetseg; Cai Dewei; Miller Eric; Swoboda Rolf; Mayer Ted; Klein-Szanto Andres; Marincola Francesco M; Mick Rosemarie; Otvos Laszlo; Wunner William; Birebent Brigitte; Somasundaram Rajasekharan; Wikstrand Carol J; Bigner Darell; DeMichele Angela; Acs Geza; Berlin Jesse A; Herlyn Dorothee
Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R).
Journal of immunology (Baltimore, Md. : 1950) 2004;173(10):6472-80.
2004: Shankar Sriram; Vaidyanathan Ganesan; Affleck Donna J; Peixoto Katia; Bigner Darell D; Zalutsky Michael R
Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
Nuclear medicine and biology 2004;31(7):909-19.
2004: Bacolod Manny D; Johnson Stewart P; Pegg Anthony E; Dolan M Eileen; Moschel Robert C; Bullock Nancy S; Fang Qingming; Colvin O Michael; Modrich Paul; Bigner Darell D; Friedman Henry S
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Molecular cancer therapeutics 2004;3(9):1127-35.
2004: Boskovitz Abraham; Wikstrand Carol J; Kuan Chien-Tsun; Zalutsky Michael R; Reardon David A; Bigner Darell D
Monoclonal antibodies for brain tumour treatment.
Expert opinion on biological therapy 2004;4(9):1453-71.
2004: Broderick Daniel K; Di Chunhui; Parrett Timothy J; Samuels Yardena R; Cummins Jordan M; McLendon Roger E; Fults Daniel W; Velculescu Victor E; Bigner Darell D; Yan Hai
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Cancer research 2004;64(15):5048-50.
2004: Wiltshire Rodney N; Herndon James E; Lloyd Annie; Friedman Henry S; Bigner Darell D; Bigner Sandra H; McLendon Roger E
Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.
The Journal of molecular diagnostics : JMD 2004;6(3):166-79.
2004: Rizzieri David A; Akabani Gamal; Zalutsky Michael R; Coleman R Edward; Metzler Scott D; Bowsher James E; Toaso Bonnie; Anderson Elizabeth; Lagoo Anand; Clayton Steve; Pegram Charles N; Moore Joseph O; Gockerman Jon P; DeCastro Carlos; Gasparetto Cristina; Chao Nelson J; Bigner Darell D
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.
Blood 2004;104(3):642-8.
2004: Merrill Melinda K; Bernhardt Guenter; Sampson John H; Wikstrand Carol J; Bigner Darell D; Gromeier Matthias
Poliovirus receptor CD155-targeted oncolysis of glioma.
Neuro-oncology 2004;6(3):208-17.
2004: Hjelmeland Mark D; Hjelmeland Anita B; Sathornsumetee Sith; Reese Elizabeth D; Herbstreith Michael H; Laping Nicholas J; Friedman Henry S; Bigner Darell D; Wang Xiao-Fan; Rich Jeremy N
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.
Molecular cancer therapeutics 2004;3(6):737-45.
2004: Rich Jeremy N; Bigner Darell D
Development of novel targeted therapies in the treatment of malignant glioma.
Nature reviews. Drug discovery 2004;3(5):430-46.
2004: Learn Chris A; Hartzell Tristan L; Wikstrand Carol J; Archer Gary E; Rich Jeremy N; Friedman Allan H; Friedman Henry S; Bigner Darell D; Sampson John H
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):3216-24.
2004: Quinn Jennifer A; Reardon David A; Friedman Allan H; Rich Jeremy N; Sampson John H; Vredenburgh James; Gururangan Sridharan; Provenzale James M; Walker Amy; Schweitzer Holly; Bigner Darell D; Tourt-Uhlig Sandra; Herndon James E; Affronti Mary Lou; Jackson Susanne; Allen Deborah; Ziegler Karen; Bohlin Cindy; Lentz Christy; Friedman Henry S
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Neuro-oncology 2004;6(2):145-53.
2004: Reardon David A; Quinn Jennifer A; Rich Jeremy N; Gururangan Sridharan; Vredenburgh James; Sampson John H; Provenzale James M; Walker Amy; Badruddoja Michael; Tourt-Uhlig Sandra; Herndon James E; Dowell Jeannette M; Affronti Mary Lou; Jackson Susanne; Allen Deborah; Ziegler Karen; Silverman Steven; Bohlin Cindy; Friedman Allan H; Bigner Darell D; Friedman Henry S
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Neuro-oncology 2004;6(2):134-44.
2004: Boskovitz Abraham; Akabani Gamal H; Pegram Charles N; Bigner Darrell D; Zalutsky Michael R
Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.
Nuclear medicine and biology 2004;31(3):345-55.
2004: Castillo Monette S; Davis Faith G; Surawicz Tanya; Bruner Janet M; Bigner Sandra; Coons Stephen; Bigner Darell D
Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems.
Neuroepidemiology 2004;23(1-2):85-93.
2004: Rich Jeremy N; Reardon David A; Peery Terry; Dowell Jeannette M; Quinn Jennifer A; Penne Kara L; Wikstrand Carol J; Van Duyn Lauren B; Dancey Janet E; McLendon Roger E; Kao James C; Stenzel Timothy T; Ahmed Rasheed B K; Tourt-Uhlig Sandra E; Herndon James E; Vredenburgh James J; Sampson John H; Friedman Allan H; Bigner Darell D; Friedman Henry S
Phase II trial of gefitinib in recurrent glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):133-42.
2003: Grossi Peter M; Ochiai Hidenobu; Archer Gary E; McLendon Roger E; Zalutsky Michael R; Friedman Allan H; Friedman Henry S; Bigner Darell D; Sampson John H
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5514-20.
2003: Sampson John H; Akabani Gamal; Archer Gary E; Bigner Darell D; Berger Mitchel S; Friedman Allan H; Friedman Henry S; Herndon James E; Kunwar Sandeep; Marcus Steve; McLendon Roger E; Paolino Alison; Penne Kara; Provenzale James; Quinn Jennifer; Reardon David A; Rich Jeremy; Stenzel Timothy; Tourt-Uhlig Sandra; Wikstrand Carol; Wong Terence; Williams Roger; Yuan Fan; Zalutsky Michael R; Pastan Ira
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
Journal of neuro-oncology 2003;65(1):27-35.
2003: Heimberger Amy B; Crotty Laura E; Archer Gary E; Hess Kenneth R; Wikstrand Carol J; Friedman Allan H; Friedman Henry S; Bigner Darell D; Sampson John H
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4247-54.
2003: Fecci Peter E; Mitchell Duane A; Archer Gary E; Morse Michael A; Lyerly H Kim; Bigner Darell D; Sampson John H
The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.
Journal of neuro-oncology 2003;64(1-2):161-76.
2003: Vaidyanathan Ganesan; Affleck Donna J; Bigner Darell D; Zalutsky Michael R
N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At.
Nuclear medicine and biology 2003;30(4):351-9.
2003: Rich Jeremy N; Shi Qing; Hjelmeland Mark; Cummings Thomas J; Kuan Chien-Tsun; Bigner Darell D; Counter Christopher M; Wang Xiao-Fan
Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model.
The Journal of biological chemistry 2003;278(18):15951-7.
2003: Quinn Jennifer A; Reardon David A; Friedman Allan H; Rich Jeremy N; Sampson John H; Provenzale James M; McLendon Roger E; Gururangan Sridharan; Bigner Darell D; Herndon James E; Avgeropoulos Nicholas; Finlay Jonathan; Tourt-Uhlig Sandra; Affronti Mary Lou; Evans Brandon; Stafford-Fox Valerie; Zaknoen Sara; Friedman Henry S
Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2002: Heimberger Amy B; Learn Chris A; Archer Gary E; McLendon Roger E; Chewning Tracy A; Tuck Frank L; Pracyk John B; Friedman Allan H; Friedman Henry S; Bigner Darell D; Sampson John H
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3496-502.
2002: Akabani Gamal; McLendon Roger E; Bigner Darrell D; Zalutsky Michael R
Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.
International journal of radiation oncology, biology, physics 2002;54(4):1259-75.
2002: Friedman Henry S; Keir Stephen; Pegg Anthony E; Houghton Peter J; Colvin O Michael; Moschel Robert C; Bigner Darell D; Dolan M Eileen
O6-benzylguanine-mediated enhancement of chemotherapy.
Molecular cancer therapeutics 2002;1(11):943-8.
2002: Bacolod Manny D; Johnson Stewart P; Ali-Osman Francis; Modrich Paul; Bullock Nancy S; Colvin O Michael; Bigner Darell D; Friedman Henry S
Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.
Molecular cancer therapeutics 2002;1(9):727-36.
2002: Rasheed Ahmed; Herndon James E; Stenzel Timothy T; Raetz Jacqueline G M; Kendelhardt Jason; Friedman Henry S; Friedman Allan H; Bigner Darell D; Bigner Sandra H; McLendon Roger E
Molecular markers of prognosis in astrocytic tumors.
Cancer 2002;94(10):2688-97.
2002: Quinn Jennifer A; Pluda James; Dolan M Eileen; Delaney Shannon; Kaplan Richard; Rich Jeremy N; Friedman Allan H; Reardon David A; Sampson John H; Colvin O Michael; Haglund Michael M; Pegg Anthony E; Moschel Robert C; McLendon Roger E; Provenzale James M; Gururangan Sridharan; Tourt-Uhlig Sandra; Herndon James E; Bigner Darell D; Friedman Henry S
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2277-83.
2002: Aldosari Naji; Wiltshire Rodney N; Dutra Amalia; Schrock Evelin; McLendon Roger E; Friedman Henry S; Bigner Darell D; Bigner Sandra H
Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft.
Neuro-oncology 2002;4(2):75-85.
2002: Reardon David A; Akabani Gamal; Coleman R Edward; Friedman Allan H; Friedman Henry S; Herndon James E; Cokgor Ilkcan; McLendon Roger E; Pegram Charles N; Provenzale James M; Quinn Jennifer A; Rich Jeremy N; Regalado Lorna V; Sampson John H; Shafman Timothy D; Wikstrand Carol J; Wong Terence Z; Zhao Xiao-Guang; Zalutsky Michael R; Bigner Darell D
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1389-97.
2002: Wikstrand Carol J; Cole Vanessa R; Crotty Laura E; Sampson John H; Bigner Darell D
Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
Cancer immunology, immunotherapy : CII 2002;50(12):639-52.
2002: Heimberger Amy B; Archer Gary E; Crotty Laura E; McLendon Roger E; Friedman Allan H; Friedman Henry S; Bigner Darell D; Sampson John H
Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.
Neurosurgery 2002;50(1):158-64; discussion 164-6.
2002: Vaidyanathan Ganesan; Affleck Donna J; Bigner Darell D; Zalutsky Michael R
Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
Nuclear medicine and biology 2002;29(1):1-11.
2001: Friedman H S; Keir S T; Houghton P J; Lawless A A; Bigner D D; Waters S J
Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.
Cancer chemotherapy and pharmacology 2001;48(5):413-6.
2001: Zalutsky M R; Zhao X G; Alston K L; Bigner D
High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(10):1508-15.
2001: Foulon C F; Welsh P C; Bigner D D; Zalutsky M R
Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.
Nuclear medicine and biology 2001;28(7):769-77.
2001: Keir S T; Hausheer F; Lawless A A; Bigner D D; Friedman H S
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.
Cancer chemotherapy and pharmacology 2001;48(1):83-7.
2001: Kuan C T; Wikstrand C J; Bigner D D
EGF mutant receptor vIII as a molecular target in cancer therapy.
Endocrine-related cancer 2001;8(2):83-96.
2001: Cokgor I; Akabani G; Friedman H S; Friedman A H; Zalutsky M R; Zehngebot L M; Provenzale J M; Guy C D; Wikstrand C J; Bigner D D
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study.
Cancer 2001;91(9):1809-13.
2001: Rich J N; Guo C; McLendon R E; Bigner D D; Wang X F; Counter C M
A genetically tractable model of human glioma formation.
Cancer research 2001;61(9):3556-60.
2000: Kuan C T; Wikstrand C J; Archer G; Beers R; Pastan I; Zalutsky M R; Bigner D D
Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.
International journal of cancer. Journal international du cancer 2000;88(6):962-9.
2000: Cokgor I; Akabani G; Kuan C T; Friedman H S; Friedman A H; Coleman R E; McLendon R E; Bigner S H; Zhao X G; Garcia-Turner A M; Pegram C N; Wikstrand C J; Shafman T D; Herndon J E; Provenzale J M; Zalutsky M R; Bigner D D
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(22):3862-72.
2000: Patel V J; Elion G B; Houghton P J; Keir S; Pegg A E; Johnson S P; Dolan M E; Bigner D D; Friedman H S
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):4154-7.
2000: Heimberger A B; Archer G E; McLendon R E; Hulette C; Friedman A H; Friedman H S; Bigner D D; Sampson J H
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):4148-53.
2000: Friedman H S; Pluda J; Quinn J A; Ewesuedo R B; Long L; Friedman A H; Cokgor I; Colvin O M; Haglund M M; Ashley D M; Rich J N; Sampson J; Pegg A E; Moschel R C; McLendon R E; Provenzale J M; Stewart E S; Tourt-Uhlig S; Garcia-Turner A M; Herndon J E; Bigner D D; Dolan M E
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3522-8.
2000: Foulon C F; Reist C J; Bigner D D; Zalutsky M R
Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Cancer research 2000;60(16):4453-60.
2000: McLendon R E; Wikstrand C J; Matthews M R; Al-Baradei R; Bigner S H; Bigner D D
Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2000;48(8):1103-10.
2000: Sampson J H; Crotty L E; Lee S; Archer G E; Ashley D M; Wikstrand C J; Hale L P; Small C; Dranoff G; Friedman A H; Friedman H S; Bigner D D
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(13):7503-8.
2000: Aldosari N; Rasheed B K; McLendon R E; Friedman H S; Bigner D D; Bigner S H
Characterization of chromosome 17 abnormalities in medulloblastomas.
Acta neuropathologica 2000;99(4):345-51.
2000: Akabani G; Cokgor I; Coleman R E; González Trotter D; Wong T Z; Friedman H S; Friedman A H; Garcia-Turner A; Herndon J E; DeLong D; McLendon R E; Zhao X G; Pegram C N; Provenzale J M; Bigner D D; Zalutsky M R
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
International journal of radiation oncology, biology, physics 2000;46(4):947-58.
2000: Heimberger A B; Crotty L E; Archer G E; McLendon R E; Friedman A; Dranoff G; Bigner D D; Sampson J H
Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma.
Journal of neuroimmunology 2000;103(1):16-25.
2000: Kuan C T; Wikstrand C J; Bigner D D
EGFRvIII as a promising target for antibody-based brain tumor therapy.
Brain tumor pathology 2000;17(2):71-8.
2000: Keir S T; Dolan M E; Pegg A E; Lawless A; Moschel R C; Bigner D D; Friedman H S
O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.
Cancer chemotherapy and pharmacology 2000;45(6):437-40.
2000: Castellino R C; Elion G B; Keir S T; Houghton P J; Johnson S P; Bigner D D; Friedman H S
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Cancer chemotherapy and pharmacology 2000;45(4):345-9.
1999: Rich J N; Zhang M; Datto M B; Bigner D D; Wang X F
Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines.
The Journal of biological chemistry 1999;274(49):35053-8.
1999: Foulon C F; Bigner D D; Zalutsky M R
Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
Bioconjugate chemistry 1999;10(5):867-76.
1999: Archer G E; Sampson J H; Lorimer I A; McLendon R E; Kuan C T; Friedman A H; Friedman H S; Pastan I H; Bigner D D
Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2646-52.
1999: McLendon R E; Archer G E; Larsen R H; Akabani G; Bigner D D; Zalutsky M R
Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.
International journal of radiation oncology, biology, physics 1999;45(2):491-9.
1999: Bigner S H; Matthews M R; Rasheed B K; Wiltshire R N; Friedman H S; Friedman A H; Stenzel T T; Dawes D M; McLendon R E; Bigner D D
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
The American journal of pathology 1999;155(2):375-86.
1999: Kuan C T; Reist C J; Foulon C F; Lorimer I A; Archer G; Pegram C N; Pastan I; Zalutsky M R; Bigner D D
125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1539-49.
1999: Reist C J; Foulon C F; Alston K; Bigner D D; Zalutsky M R
Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
Nuclear medicine and biology 1999;26(4):405-11.
1999: Sampson J H; Archer G E; Villavicencio A T; McLendon R E; Friedman A H; Bishop W R; Bigner D D; Friedman H S
Treatment of neoplastic meningitis with intrathecal temozolomide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(5):1183-8.
1999: Friedman H S; Petros W P; Friedman A H; Schaaf L J; Kerby T; Lawyer J; Parry M; Houghton P J; Lovell S; Rasheed K; Cloughsey T; Stewart E S; Colvin O M; Provenzale J M; McLendon R E; Bigner D D; Cokgor I; Haglund M; Rich J; Ashley D; Malczyn J; Elfring G L; Miller L L
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1516-25.
1999: Rasheed B K; Wiltshire R N; Bigner S H; Bigner D D
Molecular pathogenesis of malignant gliomas.
Current opinion in oncology 1999;11(3):162-7.
1999: Akabani G; Reist C J; Cokgor I; Friedman A H; Friedman H S; Coleman R E; Zhao X G; Bigner D D; Zalutsky M R
Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(4):631-8.
1999: Wikstrand C J; Cokgor I; Sampson J H; Bigner D D
Monoclonal antibody therapy of human gliomas: current status and future approaches.
Cancer metastasis reviews 1999;18(4):451-64.
1999: Archer G E; Sampson J H; McLendon R E; Friedman A H; Colvin O M; Rose M; Sands H; McCullough W; Fuchs H E; Bigner D D; Friedman H S
Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.
Journal of neuro-oncology 1999;44(3):233-41.
1999: Friedman H S; Pegg A E; Johnson S P; Loktionova N A; Dolan M E; Modrich P; Moschel R C; Struck R; Brent T P; Ludeman S; Bullock N; Kilborn C; Keir S; Dong Q; Bigner D D; Colvin O M
Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.
Cancer chemotherapy and pharmacology 1999;43(1):80-5.
1999: Dong Q; Johnson S P; Colvin O M; Bullock N; Kilborn C; Runyon G; Sullivan D M; Easton J; Bigner D D; Nahta R; Marks J; Modrich P; Friedman H S
Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR).
Cancer chemotherapy and pharmacology 1999;43(1):73-9.
1998: Friedman H S; McLendon R E; Kerby T; Dugan M; Bigner S H; Henry A J; Ashley D M; Krischer J; Lovell S; Rasheed K; Marchev F; Seman A J; Cokgor I; Rich J; Stewart E; Colvin O M; Provenzale J M; Bigner D D; Haglund M M; Friedman A H; Modrich P L
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3851-7.
1998: Friedman H S; Kokkinakis D M; Pluda J; Friedman A H; Cokgor I; Haglund M M; Ashley D M; Rich J; Dolan M E; Pegg A E; Moschel R C; McLendon R E; Kerby T; Herndon J E; Bigner D D; Schold S C
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3570-5.
1998: Reist C J; Bigner D D; Zalutsky M R
Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2495-502.
1998: Ashley D M; Sampson J H; Archer G E; Hale L P; Bigner D D
Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model.
Journal of neuroimmunology 1998;86(1):46-52.
1998: Lee S E; Johnson S P; Hale L P; Li J; Bullock N; Fuchs H; Friedman A; McLendon R; Bigner D D; Modrich P; Friedman H S
Analysis of DNA mismatch repair proteins in human medulloblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1415-9.
1998: Bigner D D; Brown M T; Friedman A H; Coleman R E; Akabani G; Friedman H S; Thorstad W L; McLendon R E; Bigner S H; Zhao X G; Pegram C N; Wikstrand C J; Herndon J E; Vick N A; Paleologos N; Cokgor I; Provenzale J M; Zalutsky M R
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2202-12.
1998: McLendon R E; Cleveland L; Pegram C; Bigner S H; Bigner D D; Friedman H S
Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas.
Laboratory investigation; a journal of technical methods and pathology 1998;78(5):643-4.
1998: Wikstrand C J; Reist C J; Archer G E; Zalutsky M R; Bigner D D
The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
Journal of neurovirology 1998;4(2):148-58.
1998: Ashley D M; Kong F M; Bigner D D; Hale L P
Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
Cancer research 1998;58(2):302-9.
1998: Hanley M L; Elion G B; Colvin O M; Modrich P L; Keir S; Adams D J; Bigner D D; Friedman H S
Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors.
Cancer chemotherapy and pharmacology 1998;42(6):479-82.
1998: Coggins C A; Elion G B; Houghton P J; Hare C B; Keir S; Colvin O M; Bigner D D; Friedman H S
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Cancer chemotherapy and pharmacology 1998;41(6):485-90.
1997: Ashley D M; Batra S K; Bigner D D
Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors.
Journal of neuro-oncology 1997;35(3):259-73.
1997: Sampson J H; Ashley D M; Archer G E; Fuchs H E; Dranoff G; Hale L P; Bigner D D
Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.
Neurosurgery 1997;41(6):1365-72; discussion 1372-3.
1997: Reist C J; Batra S K; Pegram C N; Bigner D D; Zalutsky M R
In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent.
Nuclear medicine and biology 1997;24(7):639-47.
1997: Rasheed B K; Stenzel T T; McLendon R E; Parsons R; Friedman A H; Friedman H S; Bigner D D; Bigner S H
PTEN gene mutations are seen in high-grade but not in low-grade gliomas.
Cancer research 1997;57(19):4187-90.
1997: Ashley D M; Faiola B; Nair S; Hale L P; Bigner D D; Gilboa E
Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.
The Journal of experimental medicine 1997;186(7):1177-82.
1997: Wikstrand C J; McLendon R E; Friedman A H; Bigner D D
Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
Cancer research 1997;57(18):4130-40.
1997: Ashley D M; Sampson J H; Archer G E; Batra S K; Bigner D D; Hale L P
A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.
Journal of neuroimmunology 1997;78(1-2):34-46.
1997: Friedman H S; Johnson S P; Dong Q; Schold S C; Rasheed B K; Bigner S H; Ali-Osman F; Dolan E; Colvin O M; Houghton P; Germain G; Drummond J T; Keir S; Marcelli S; Bigner D D; Modrich P
Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.
Cancer research 1997;57(14):2933-6.
1997: Archer G E; Sampson J H; Bigner D D
Viruses and oncogenes in brain tumors.
Journal of neurovirology 1997;3 Suppl 1():S76-7.
1997: Zalutsky M R; Stabin M G; Larsen R H; Bigner D D
Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.
Nuclear medicine and biology 1997;24(3):255-61.
1997: Reist C J; Archer G E; Wikstrand C J; Bigner D D; Zalutsky M R
Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Cancer research 1997;57(8):1510-5.
1997: Hauck M L; Dewhirst M W; Bigner D D; Zalutsky M R
Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(1):63-70.
1997: Hare C B; Elion G B; Colvin O M; Ali-Osman F; Griffith O W; Petros W P; Keir S; Marcelli S L; Bigner D D; Friedman H S
Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.
Cancer chemotherapy and pharmacology 1997;40(5):409-14.
1997: Hare C B; Elion G B; Houghton P J; Houghton J A; Keir S; Marcelli S L; Bigner D D; Friedman H S
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Cancer chemotherapy and pharmacology 1997;39(3):187-91.
1997: Moynihan K; Elion G B; Pegram C; Reist C J; Wellner D; Bigner D D; Griffith O W; Friedman H S
L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma.
Cancer chemotherapy and pharmacology 1997;39(3):179-86.
1996: Lorimer I A; Keppler-Hafkemeyer A; Beers R A; Pegram C N; Bigner D D; Pastan I
Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(25):14815-20.
1996: Reist C J; Garg P K; Alston K L; Bigner D D; Zalutsky M R
Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Cancer research 1996;56(21):4970-7.
1996: Sampson J H; Archer G E; Ashley D M; Fuchs H E; Hale L P; Dranoff G; Bigner D D
Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(19):10399-404.
1996: McCowage G; Tien R; McLendon R; Felsberg G; Fuchs H; Graham M L; Kurtzberg J; Moghrabi A; Ferrell L; Kerby T; Duncan-Brown M; Stewart E; Robertson P L; Colvin O M; Golembe B; Bigner D D; Friedman H S
Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide.
Medical and pediatric oncology 1996;27(1):32-9.
1996: Brown M T; Coleman R E; Friedman A H; Friedman H S; McLendon R E; Reiman R; Felsberg G J; Tien R D; Bigner S H; Zalutsky M R; Zhao X G; Wikstrand C J; Pegram C N; Herndon J E; Vick N A; Paleologos N; Fredericks R K; Schold S C; Bigner D D
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(6):963-72.
1996: Fredman P; Wikstrand C J; Månsson J E; Reifenberger G; Bigner S H; Rasheed A; Svennerholm L; Bigner D D
In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line.
Glycoconjugate journal 1996;13(3):391-9.
1996: Ashley D M; Longee D; Tien R; Fuchs H; Graham M L; Kurtzberg J; Casey J; Olson J; Meier L; Ferrell L; Kerby T; Duncan-Brown M; Stewart E; Colvin O M; Pipas J M; McCowage G; McLendon R; Bigner D D; Friedman H S
Treatment of patients with pineoblastoma with high dose cyclophosphamide.
Medical and pediatric oncology 1996;26(6):387-92.
1996: Zalutsky M R; Archer G E; Garg P K; Batra S K; Bigner D D
Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.
Nuclear medicine and biology 1996;23(4):449-58.
1996: McLendon R E; Fung K M; Bentley R C; Ahmed Rasheed B K; Trojanowski J Q; Bigner S H; Bigner D D; Friedman H S
Production and characterization of two ependymoma xenografts.
Journal of neuropathology and experimental neurology 1996;55(5):540-8.
1996: McLendon R E; Archer G E; Garg P K; Bigner D D; Zalutsky M R
Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis.
International journal of radiation oncology, biology, physics 1996;35(1):69-80.
1996: Zalutsky M R; Schuster J M; Garg P K; Archer G E; Dewhirst M W; Bigner D D
Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1996;141():101-22.
1996: Zalutsky M R; Bigner D D
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
Acta oncologica (Stockholm, Sweden) 1996;35(3):373-9.
1996: Moynihan K; Elion G B; Ali-Osman F; Marcelli S; Keir S; Bigner D D; Friedman H S
Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta.
Cancer chemotherapy and pharmacology 1996;38(4):349-54.
1996: Dong Q; Bullock N; Ali-Osman F; Colvin O M; Bigner D D; Friedman H S
Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines.
Cancer chemotherapy and pharmacology 1996;37(3):242-46.
1995: Bigner D D; Archer G E; McLendon R E; Friedman H S; Fuchs H E; Pai L H; Herndon J E; Pastan I H
Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(12):1545-55.
1995: Dong Q; Barsky D; Colvin M E; Melius C F; Ludeman S M; Moravek J F; Colvin O M; Bigner D D; Modrich P; Friedman H S
A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC).
Proceedings of the National Academy of Sciences of the United States of America 1995;92(26):12170-4.
1995: Kurpad S N; Zhao X G; Wikstrand C J; Batra S K; McLendon R E; Bigner D D
Tumor antigens in astrocytic gliomas.
Glia 1995;15(3):244-56.
1995: Batra S K; Castelino-Prabhu S; Wikstrand C J; Zhu X; Humphrey P A; Friedman H S; Bigner D D
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1995;6(10):1251-9.
1995: Reist C J; Archer G E; Kurpad S N; Wikstrand C J; Vaidyanathan G; Willingham M C; Moscatello D K; Wong A J; Bigner D D; Zalutsky M R
Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
Cancer research 1995;55(19):4375-82.
1995: Kurpad S N; Friedman H S; Archer G E; McLendon R E; Petros W M; Fuchs H E; Guaspari A; Bigner D D
Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats.
Cancer research 1995;55(17):3803-9.
1995: Lorimer I A; Wikstrand C J; Batra S K; Bigner D D; Pastan I
Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(8):859-64.
1995: Friedman H S; Dolan M E; Pegg A E; Marcelli S; Keir S; Catino J J; Bigner D D; Schold S C
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
Cancer research 1995;55(13):2853-7.
1995: Rasheed B K; McLendon R E; Friedman H S; Friedman A H; Fuchs H E; Bigner D D; Bigner S H
Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25.
Oncogene 1995;10(11):2243-6.
1995: Castellino S M; Friedman H S; Elion G B; Ong E T; Marcelli S L; Page R; Bigner D D; Dewhirst M W
Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.
British journal of cancer 1995;71(6):1181-7.
1995: Foltz R M; McLendon R E; Friedman H S; Dodge R K; Bigner D D; Dewhirst M W
A pial window model for the intracranial study of human glioma microvascular function.
Neurosurgery 1995;36(5):976-84; discussion 984-5.
1995: Pastan I H; Archer G E; McLendon R E; Friedman H S; Fuchs H E; Wang Q C; Pai L H; Herndon J; Bigner D D
Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(7):2765-9.
1995: Schuster J M; Zalutsky M R; Noska M A; Dodge R; Friedman H S; Bigner D D; Dewhirst M W
Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1995;11(1):59-72.
1995: Batra S K; McLendon R E; Koo J S; Castelino-Prabhu S; Fuchs H E; Krischer J P; Friedman H S; Bigner D D; Bigner S H
Prognostic implications of chromosome 17p deletions in human medulloblastomas.
Journal of neuro-oncology 1995;24(1):39-45.
1995: Bigner D D; Brown M; Coleman R E; Friedman A H; Friedman H S; McLendon R E; Bigner S H; Zhao X G; Wikstrand C J; Pegram C N
Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
Journal of neuro-oncology 1995;24(1):109-22.
1995: Friedman H S; Bigner S H; Bigner D D
Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).
Journal of neuro-oncology 1995;24(1):103-8.
1994: Batra S K; Rasheed B K; Bigner S H; Bigner D D
Oncogenes and anti-oncogenes in human central nervous system tumors.
Laboratory investigation; a journal of technical methods and pathology 1994;71(5):621-37.
1994: Zalutsky M R; McLendon R E; Garg P K; Archer G E; Schuster J M; Bigner D D
Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
Cancer research 1994;54(17):4719-25.
1994: Friedman H S; Archer G E; McLendon R E; Schuster J M; Colvin O M; Guaspari A; Blum R; Savina P A; Fuchs H E; Bigner D D
Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats.
Cancer research 1994;54(17):4710-4.
1994: Friedman H S; Dolan M E; Kaufmann S H; Colvin O M; Griffith O W; Moschel R C; Schold S C; Bigner D D; Ali-Osman F
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Cancer research 1994;54(13):3487-93.
1994: McLendon R E; Bigner D D
Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations.
Brain pathology (Zurich, Switzerland) 1994;4(3):221-8.
1994: He X; Archer G E; Wikstrand C J; Morrison S L; Zalutsky M R; Bigner D D; Batra S K
Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.
Journal of neuroimmunology 1994;52(2):127-37.
1994: Kurpad S N; Wikstrand C J; Bigner D D
Immunobiology of malignant astrocytomas.
Seminars in oncology 1994;21(2):149-61.
1994: Batra S K; Niswonger M L; Wikstrand C J; Pegram C N; Zalutsky M R; Morrison S L; Bigner D D
Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.
Hybridoma 1994;13(2):87-97.
1994: Rasheed B K; McLendon R E; Herndon J E; Friedman H S; Friedman A H; Bigner D D; Bigner S H
Alterations of the TP53 gene in human gliomas.
Cancer research 1994;54(5):1324-30.
1994: Wikstrand C J; Fredman P; McLendon R R; Svennerholm L; Bigner D D
Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro.
Molecular and chemical neuropathology / sponsored by the International Society for Neurochemistry and the World Federation of Neurology and research groups on neurochemistry and cerebrospinal fluid 1994;21(2-3):129-38.
1994: Friedman H S; Houghton P J; Schold S C; Keir S; Bigner D D
Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.
Cancer chemotherapy and pharmacology 1994;34(2):171-4.
1994: Aaron R H; Elion G B; Colvin O M; Graham M; Keir S; Bigner D D; Friedman H S
Busulfan therapy of central nervous system xenografts in athymic mice.
Cancer chemotherapy and pharmacology 1994;35(2):127-31.
1994: Wikstrand C J; Fredman P; Svennerholm L; Bigner D D
Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies.
Progress in brain research 1994;101():213-23.
1993: Garg S; Garg P K; Zhao X G; Friedman H S; Bigner D D; Zalutsky M R
Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Nuclear medicine and biology 1993;20(7):835-42.
1993: Ibrahim S N; Lightner V A; Ventimiglia J B; Ibrahim G K; Walther P J; Bigner D D; Humphrey P A
Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma.
Human pathology 1993;24(9):982-9.
1993: Wikstrand C J; Stanley S D; Humphrey P A; Pegram C N; Archer G E; Kurpad S; Shibuya M; Bigner D D
Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas.
Journal of neuroimmunology 1993;46(1-2):165-73.
1993: Schold S C; Zalutsky M R; Coleman R E; Glantz M J; Friedman A H; Jaszczak R J; Bigner S H; Bigner D D
Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.
Investigative radiology 1993;28(6):488-96.
1993: Schuster J M; Friedman H S; Archer G E; Fuchs H E; McLendon R E; Colvin O M; Bigner D D
Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.
Cancer research 1993;53(10 Suppl):2338-43.
1993: Schold S C; Herndon J E; Burger P C; Halperin E C; Vick N A; Cairncross J G; Macdonald D R; Dropcho E J; Morawetz R; Bigner D D
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):77-83.
1993: Wikstrand C J; Longee D C; McLendon R E; Fuller G N; Friedman H S; Fredman P; Svennerholm L; Bigner D D
Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo.
Cancer research 1993;53(1):120-6.
1993: Castellino S; Elion G B; Griffith O W; Dewhirst M; Kurtzberg J; Cattley R C; Scott P; Bigner D D; Friedman H S
Development of a model of melphalan-induced gastrointestinal toxicity in mice.
Cancer chemotherapy and pharmacology 1993;31(5):376-80.
1993: Brent T P; von Wronski M A; Edwards C C; Bromley M; Margison G P; Rafferty J A; Pegram C N; Bigner D D
Identification of nitrosourea-resistant human rhabdomyosarcomas by in situ immunostaining of O6-methylguanine-DNA methyltransferase.
Oncology research 1993;5(2):83-6.
1992: Bigner D D
M. Stephen Mahaley, Jr., M.D., Ph.D., 1932-1992.
Journal of neurosurgery 1992;77(6):829-31.
1992: Friedman H S; Dolan M E; Moschel R C; Pegg A E; Felker G M; Rich J; Bigner D D; Schold S C
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
Journal of the National Cancer Institute 1992;84(24):1926-31.
1992: Wikstrand C J; Fredman P; Svennerholm L; Humphrey P A; Bigner S H; Bigner D D
Monoclonal antibodies to malignant human gliomas.
Molecular and chemical neuropathology / sponsored by the International Society for Neurochemistry and the World Federation of Neurology and research groups on neurochemistry and cerebrospinal fluid 1992;17(2):137-46.
1992: Friedman H S; Colvin O M; Kaufmann S H; Ludeman S M; Bullock N; Bigner D D; Griffith O W
Cyclophosphamide resistance in medulloblastoma.
Cancer research 1992;52(19):5373-8.
1992: Vick W W; Tello J W; Wikstrand C J; He X; Longee D; Fredman P; Svennerholm L; Bigner D D; Johnston W W; Bigner S H
Application of a panel of antiganglioside monoclonal antibodies to cytologic specimens.
Acta cytologica 1992;36(5):697-705.
1992: Garg P K; Garg S; Bigner D D; Zalutsky M R
Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model.
Cancer research 1992;52(18):5054-60.
1992: Vaidyanathan G; Bigner D D; Zalutsky M R
Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(8):1535-41.
1992: Moseley R P; Papanastassiou V; Zalutsky M R; Ashpole R D; Evans S; Bigner D D; Kemshead J T
Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.
International journal of cancer. Journal international du cancer 1992;52(1):38-43.
1992: Rasheed B K; Fuller G N; Friedman A H; Bigner D D; Bigner S H
Loss of heterozygosity for 10q loci in human gliomas.
Genes, chromosomes & cancer 1992;5(1):75-82.
1992: Schuster J M; Bigner D D
Immunotherapy and monoclonal antibody therapies.
Current opinion in oncology 1992;4(3):547-52.
1992: Laskowitz D T; Elion G B; Dewhirst M W; Griffith O W; Casero R A; Scott P A; Bullock N; Bigner D D; Friedman H S
Effects of glutathione or polyamine depletion on in vivo thermosensitization.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1992;8(2):199-208.
1992: Kwatra M M; Bigner D D; Cohn J A
The ligand binding domain of the epidermal growth factor receptor is not required for receptor dimerization.
Biochimica et biophysica acta 1992;1134(2):178-81.
1992: Laskowitz D T; Elion G B; Dewhirst M W; Griffith O W; Savina P M; Blum M R; Prescott D M; Bigner D D; Friedman H S
Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.
Radiation research 1992;129(2):218-23.
1992: Shiota S; von Wronski M A; Tano K; Bigner D D; Brent T P; Mitra S
Characterization of cDNA encoding mouse DNA repair protein O6-methylguanine-DNA methyltransferase and high-level expression of the wild-type and mutant proteins in Escherichia coli.
Biochemistry 1992;31(7):1897-903.
1992: Laskowitz D T; Elion G B; Dewhirst M W; Griffith O W; Cattley R C; Bigner D D; Friedman H S
Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1992;8(1):111-20.
1992: Ventimiglia J B; Wikstrand C J; Ostrowski L E; Bourdon M A; Lightner V A; Bigner D D
Tenascin expression in human glioma cell lines and normal tissues.
Journal of neuroimmunology 1992;36(1):41-55.
1992: Halperin E C; Brizel D M; Honore G; Sontag M R; Griffith O W; Bigner D D; Friedman H S
The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine.
International journal of radiation oncology, biology, physics 1992;24(1):103-9.
1992: von Wronski M A; Harris L C; Tano K; Mitra S; Bigner D D; Brent T P
Cytosine methylation and suppression of O6-methylguanine-DNA methyltransferase expression in human rhabdomyosarcoma cell lines and xenografts.
Oncology research 1992;4(4-5):167-74.
1991: Wikstrand C J; He X M; Fuller G N; Bigner S H; Fredman P; Svennerholm L; Bigner D D
Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo.
Journal of neuropathology and experimental neurology 1991;50(6):756-69.
1991: Tano K; Shiota S; Remack J S; Brent T P; Bigner D D; Mitra S
The origin of O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells transfected with human DNA.
Mutation research 1991;255(2):175-82.
1991: Ostrowski L E; von Wronski M A; Bigner S H; Rasheed A; Schold S C; Brent T P; Mitra S; Bigner D D
Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines.
Carcinogenesis 1991;12(9):1739-44.
1991: Bjerkvig R; Engebraaten O; Laerum O D; Fredman P; Svennerholm L; Vrionis F D; Wikstrand C J; Bigner D D
Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line.
Cancer research 1991;51(17):4643-8.
1991: Friedman H S; Oakes W J; Bigner S H; Wikstrand C J; Bigner D D
Medulloblastoma: tumor biological and clinical perspectives.
Journal of neuro-oncology 1991;11(1):1-15.
1991: Lilley E R; Elion G B; Dewhirst M W; Schold S C; Blum M R; Savina P M; Laskowitz D T; Bigner D D; Friedman H S
Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.
Cancer research 1991;51(15):3906-9.
1991: Schuster J M; Garg P K; Bigner D D; Zalutsky M R
Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
Cancer research 1991;51(16):4164-9.
1991: Humphrey P A; Gangarosa L M; Wong A J; Archer G E; Lund-Johansen M; Bjerkvig R; Laerum O D; Friedman H S; Bigner D D
Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.
Biochemical and biophysical research communications 1991;178(3):1413-20.
1991: Ostrowski L E; Pegram C N; Von Wronski M A; Humphrey P A; He X M; Shiota S; Mitra S; Brent T P; Bigner D D
Production and characterization of antipeptide antibodies against human O6-methylguanine-DNA methyltransferase.
Cancer research 1991;51(13):3339-44.
1991: He X M; Wikstrand C J; Friedman H S; Bigner S H; Pleasure S; Trojanowski J Q; Bigner D D
Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts.
Laboratory investigation; a journal of technical methods and pathology 1991;64(6):833-43.
1991: Schuster J M; Friedman H S; Bigner D D
Therapeutic analysis of in vitro and in vivo brain tumor models.
Neurologic clinics 1991;9(2):375-82.
1991: Gottfries J; Percy A K; Månsson J E; Fredman P; Wikstrand C J; Friedman H S; Bigner D D; Svennerholm L
Glycolipids and glycosyltransferases in permanent cell lines established from human medulloblastomas.
Biochimica et biophysica acta 1991;1081(3):253-61.
1991: von Wronski M A; Shiota S; Tano K; Mitra S; Bigner D D; Brent T P
Structural and immunological comparison of indigenous human O6-methylguanine-DNA methyltransferase with that encoded by a cloned cDNA.
The Journal of biological chemistry 1991;266(2):1064-70.
1991: Wang A M; Elion G B; Friedman H S; Bodell W J; Bigner D D; Schold S C
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.
Cancer chemotherapy and pharmacology 1991;27(4):278-84.
1991: Wikstrand C J; Friedman H S; Bigner D D
Medulloblastoma cell-substrate interaction in vitro.
Invasion & metastasis 1991;11(6):310-24.
1991: Longee D C; Wikstrand C J; Månsson J E; He X; Fuller G N; Bigner S H; Fredman P; Svennerholm L; Bigner D D
Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.
Acta neuropathologica 1991;82(1):45-54.
1990: Bigner S H; Humphrey P A; Wong A J; Vogelstein B; Mark J; Friedman H S; Bigner D D
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.
Cancer research 1990;50(24):8017-22.
1990: Gottfries J; Fredman P; Månsson J E; Collins V P; von Holst H; Armstrong D D; Percy A K; Wikstrand C J; Bigner D D; Svennerholm L
Determination of gangliosides in six human primary medulloblastomas.
Journal of neurochemistry 1990;55(4):1322-6.
1990: Lund-Johansen M; Bjerkvig R; Humphrey P A; Bigner S H; Bigner D D; Laerum O D
Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.
Cancer research 1990;50(18):6039-44.
1990: Fredman P; Månsson J E; Bigner S H; Wikstrand C J; Bigner D D; Svennerholm L
Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats.
Biochimica et biophysica acta 1990;1045(3):239-44.
1990: Bigner S H; Mark J; Bigner D D
Cytogenetics of human brain tumors.
Cancer genetics and cytogenetics 1990;47(2):141-54.
1990: Zalutsky M R; Moseley R P; Benjamin J C; Colapinto E V; Fuller G N; Coakham H P; Bigner D D
Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.
Cancer research 1990;50(13):4105-10.
1990: Humphrey P A; Wong A J; Vogelstein B; Zalutsky M R; Fuller G N; Archer G E; Friedman H S; Kwatra M M; Bigner S H; Bigner D D
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(11):4207-11.
1990: Oakes W J; Friedman H S; Bigner S H; Bullock N H; Bigner D D
Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples. Technical note.
Journal of neurosurgery 1990;72(5):821-3.
1990: Shoup S A; Johnston W W; Siegler H F; Tello J W; Schlom J; Bigner D D; Bigner S H
A panel of antibodies useful in the cytologic diagnosis of metastatic melanoma.
Acta cytologica 1990;34(3):385-92.
1990: Bigner S H; Friedman H S; Vogelstein B; Oakes W J; Bigner D D
Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts.
Cancer research 1990;50(8):2347-50.
1990: Karlsson G; Månsson J E; Wikstrand C; Bigner D; Svennerholm L
Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2.
Biochimica et biophysica acta 1990;1043(3):267-72.
1990: Colapinto E V; Zalutsky M R; Archer G E; Noska M A; Friedman H S; Carrel S; Bigner D D
Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
Cancer research 1990;50(6):1822-7.
1990: Cope D A; Dewhirst M W; Friedman H S; Bigner D D; Zalutsky M R
Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia.
Cancer research 1990;50(6):1803-9.
1990: Fuchs H E; Archer G E; Colvin O M; Bigner S H; Schuster J M; Fuller G N; Muhlbaier L H; Schold S C; Friedman H S; Bigner D D
Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis.
Cancer research 1990;50(6):1954-9.
1990: Lippitz B E; Halperin E C; Griffith O W; Colvin O M; Honore G; Ostertag C B; Bigner D D; Friedman H S
L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice.
Neurosurgery 1990;26(2):255-60.
1990: Brent T P; von Wronski M; Pegram C N; Bigner D D
Immunoaffinity purification of human O6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies.
Cancer research 1990;50(1):58-61.
1990: Lilley E R; Rosenberg M C; Elion G B; Colvin O M; Bigner D D; Friedman H S
Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.
Cancer research 1990;50(2):284-7.
1989: Rosenberg M C; Colvin O M; Griffith O W; Bigner S H; Elion G B; Horton J K; Lilley E; Bigner D D; Friedman H S
Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
Cancer research 1989;49(24 Pt 1):6917-22.
1989: Vrionis F D; Wikstrand C J; Fredman P; Månsson J E; Svennerholm L; Bigner D D
Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.
Cancer research 1989;49(23):6645-51.
1989: Zalutsky M R; Noska M A; Colapinto E V; Garg P K; Bigner D D
Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
Cancer research 1989;49(20):5543-9.
1989: Zalutsky M R; Garg P K; Friedman H S; Bigner D D
Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(18):7149-53.
1989: Bigner S H; Schold S C; Friedman H S; Mark J; Bigner D D
Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice.
Cancer genetics and cytogenetics 1989;40(1):111-20.
1989: Fredman P; Månsson J E; Wikstrand C J; Vrionis F D; Rynmark B M; Bigner D D; Svennerholm L
A new ganglioside of the lactotetraose series, GalNAc-3'-isoLM1, detected in human meconium.
The Journal of biological chemistry 1989;264(21):12122-5.
1989: Lightner V A; Gumkowski F; Bigner D D; Erickson H P
Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy.
The Journal of cell biology 1989;108(6):2483-93.
1989: Zalutsky M R; Moseley R P; Coakham H B; Coleman R E; Bigner D D
Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.
Cancer research 1989;49(10):2807-13.
1989: Schold S C; Brent T P; von Hofe E; Friedman H S; Mitra S; Bigner D D; Swenberg J A; Kleihues P
O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.
Journal of neurosurgery 1989;70(4):573-7.
1989: Friedman H S; Colvin O M; Griffith O W; Lippitz B; Elion G B; Schold S C; Hilton J; Bigner D D
Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.
Journal of the National Cancer Institute 1989;81(7):524-7.
1989: He X M; Skapek S X; Wikstrand C J; Friedman H S; Trojanowski J Q; Kemshead J T; Coakham H B; Bigner S H; Bigner D D
Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts.
Journal of neuropathology and experimental neurology 1989;48(1):48-68.
1989: Gottfries J; Mansson J E; Fredman P; Wikstrand C J; Friedman H S; Bigner D D; Svennerholm L
Ganglioside mapping of a human medulloblastoma xenograft.
Acta neuropathologica 1989;77(3):283-8.
1989: von Wronski M A; Bigner D D; Brent T P
Expression of O6-alkylguanine-DNA alkyltransferase in Mer+ and Mer- human cell extracts probed with specific monoclonal antibodies.
Cancer communications 1989;1(5):323-7.
1989: He X; Wikstrand C J; Fredman P; Månsson J E; Svennerholm L; Bigner D D
GD3 expression by cultured human tumor cells of neuroectodermal origin.
Acta neuropathologica 1989;79(3):317-25.
1989: Garg P K; Archer G E; Bigner D D; Zalutsky M R
Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling.
International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes 1989;40(6):485-90.
1988: Skapek S X; Colvin O M; Griffith O W; Groothuis D R; Colapinto E V; Lee Y; Hilton J; Elion G B; Bigner D D; Friedman H S
Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts.
Biochemical pharmacology 1988;37(22):4313-7.
1988: Friedman H S; Skapek S X; Colvin O M; Elion G B; Blum M R; Savina P M; Hilton J; Schold S C; Kurtzberg J; Bigner D D
Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.
Cancer research 1988;48(19):5397-402.
1988: Colapinto E V; Humphrey P A; Zalutsky M R; Groothuis D R; Friedman H S; de Tribolet N; Carrel S; Bigner D D
Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.
Cancer research 1988;48(20):5701-7.
1988: Friedman H S; Colvin O M; Skapek S X; Ludeman S M; Elion G B; Schold S C; Jacobsen P F; Muhlbaier L H; Bigner D D
Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.
Cancer research 1988;48(15):4189-95.
1988: Bigner S H; Burger P C; Wong A J; Werner M H; Hamilton S R; Muhlbaier L H; Vogelstein B; Bigner D D
Gene amplification in malignant human gliomas: clinical and histopathologic aspects.
Journal of neuropathology and experimental neurology 1988;47(3):191-205.
1988: Skapek S X; Colvin O M; Griffith O W; Elion G B; Bigner D D; Friedman H S
Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
Cancer research 1988;48(10):2764-7.
1988: Lee Y; Bullard D E; Humphrey P A; Colapinto E V; Friedman H S; Zalutsky M R; Coleman R E; Bigner D D
Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
Cancer research 1988;48(10):2904-10.
1988: Humphrey P A; Wong A J; Vogelstein B; Friedman H S; Werner M H; Bigner D D; Bigner S H
Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.
Cancer research 1988;48(8):2231-8.
1988: Lee Y S; Bullard D E; Zalutsky M R; Coleman R E; Wikstrand C J; Friedman H S; Colapinto E V; Bigner D D
Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.
Cancer research 1988;48(3):559-66.
1988: Bigner S H; Mark J; Friedman H S; Biegel J A; Bigner D D
Structural chromosomal abnormalities in human medulloblastoma.
Cancer genetics and cytogenetics 1988;30(1):91-101.
1988: Bigner S H; Mark J; Burger P C; Mahaley M S; Bullard D E; Muhlbaier L H; Bigner D D
Specific chromosomal abnormalities in malignant human gliomas.
Cancer research 1988;48(2):405-11.
1988: Colapinto E V; Lee Y S; Humphrey P A; Zalutsky M R; Friedman H S; Bullard D E; Bigner D D
The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.
British journal of neurosurgery 1988;2(2):179-91.
1988: Werner M H; Humphrey P A; Bigner D D; Bigner S H
Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines.
Acta neuropathologica 1988;77(2):196-201.
1988: Vrionis F D; Wikstrand C J; Bigner D D
Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies.
Annals of the New York Academy of Sciences 1988;540():64-77.
1987: Bigner S H; Wong A J; Mark J; Muhlbaier L H; Kinzler K W; Vogelstein B; Bigner D D
Relationship between gene amplification and chromosomal deviations in malignant human gliomas.
Cancer genetics and cytogenetics 1987;29(1):165-70.
1987: Vick W W; Wikstrand C J; Bullard D E; Kemshead J; Coakham H B; Schlom J; Johnston W W; Bigner D D; Bigner S H
The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system.
Acta cytologica 1987;31(6):815-24.
1983: Bourdon M A; Wikstrand C J; Furthmayr H; Matthews T J; Bigner D D
Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.
Cancer research 1983;43(6):2796-805.
1982: Wikstrand C J; Bourdon M A; Pegram C N; Bigner D D
Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin.
Journal of neuroimmunology 1982;3(1):43-62.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Darell Bigner

Research Profile (preview)

Disorders

Living Beings

Chemicals & Drugs

Procedures

Anatomy

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Darell Bigner (preview)

All Publications